Acoramidis, an oral therapy, is now approved to reduce cardiovascular-related deaths and hospitalizations in adults with hereditary or wild-type ATTR-CM.
Plozasiran, a first-in-class RNA interference therapeutic, reduced triglycerides by 80% and lowered the risk of acute pancreatitis by 83% in patients with familial chylomicronemia syndrome (FCS), earning...
In a study that assessed pericoronary adipose tissue (PCAT) density, researchers noted an association between higher PCAT density and greater coronary plaque burden and cardiovascular disease in people with...
A recent study found that non-dihydropyridine calcium channel blockers are associated with significantly less bradycardia during sinus rhythm compared with beta-blockers in patients with non-permanent...
This COVID-19 roundup includes coverage on the latest estimated number of adults with long COVID, WHO’s updated terminology for pathogens that transmit through the air, how COVID-19 vaccination reduces the...
Researchers evaluated the safety and efficacy of dextromethorphan-bupropion, an FDA approved treatment of major depression disorder, for Alzheimer disease-related agitation. This study was presented at the...
Researchers collected data from the Atherosclerosis Risk in Communities Study to determine whether heart rate variability was associated with agitation risk in individuals clinically diagnosed with dementia...
Researchers set out to determine whether microglial activation, which can trigger neuroinflammation, is associated with neuropsychiatric symptoms that often accompany Alzheimer-associated dementias,...
The FDA has approved sotatercept-csrk, the first activin signaling inhibitor therapy, for the management of patients with pulmonary arterial hypertension (PAH). Based on the Phase 3 STELLAR trial,...
